ArticleJournal of stroke2016
Effect and Safety of Rosuvastatin in Acute Ischemic Stroke.
Article in Journal of stroke, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Statin Therapy for Preventing Recurrent Stroke in Patients with Ischemic Stroke: A Systematic Review and Meta-Analysis of Randomized Controlled Trials and Observational Cohort Studies.Neuroepidemiology · 2022Pooled it
- Statin, cholesterol, and sICH after acute ischemic stroke: systematic review and meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2019Pooled it
- Comparison of statins for secondary prevention in patients with ischemic stroke or transient ischemic attack: a systematic review and network meta-analysis.BMC medicine · 2019Pooled it
- The efficacy and safety of high-dose statins in acute phase of ischemic stroke and transient ischemic attack: a systematic review.Internal and emergency medicine · 2017Pooled it
- High-dose statins for the prevention of recurrent ischemic stroke: a systematic review and meta-analysis of randomized controlled trials.Annals of Saudi medicinePooled it
- Statin initiation and early stroke recurrence in the Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke Trial (POINT) trial population.Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association · 2025Trial
- Optimal LDL-C Levels for Ischemic Stroke Prevention: A Neurologist's Perspective.Journal of lipid and atherosclerosis · 2026Review
- Contemporary Statistics of Acute Ischemic Stroke and Transient Ischemic Attack in 2021: Insights From the CRCS-K-NIH Registry.Journal of Korean medical science · 2024Review
- Dyslipidaemia in elderly and stroke patients.Indian heart journal · 2024Review
- Low-to-moderate dose statins improve the functional outcome of acute ischemic stroke with conventional medication treatment.Cardiovascular diagnosis and therapy · 2023Article
- Rationale and design of a randomised double-blind 2×2 factorial trial comparing the effect of a 3-month intensive statin and antiplatelet therapy for patients with acute mild ischaemic stroke or high-risk TIA with intracranial or extracranial atherosclerosis (INSPIRES).Stroke and vascular neurology · 2023Article
- Article
- Medical Management of Dyslipidemia for Secondary Stroke Prevention: Narrative Review.Medicina (Kaunas, Lithuania) · 2023Review
- An Expert Opinion on the Role of the Rosuvastatin/Amlodipine Single Pill Fixed Dose Combination in Cardiovascular Prevention.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2023Article
- Association of Substantia Nigra Degeneration with Poor Neurological Recovery in Basal Ganglia Infarctions.Journal of stroke · 2023Article
- The effects of socioeconomic and geographic factors on chronic phase long-term survival after stroke in South Korea.Scientific reports · 2022Article
- Hemorrhagic Transformation in Acute Ischemic Stroke: A Quantitative Systematic Review.Journal of clinical medicine · 2022Article
- Immune Cells in the BBB Disruption After Acute Ischemic Stroke: Targets for Immune Therapy?Frontiers in immunology · 2021Review
- Post-Ischaemic Immunological Response in the Brain: Targeting Microglia in Ischaemic Stroke Therapy.Brain sciences · 2020Review
- Early Acute Ischemic Stroke Management for Pharmacists.Hospital pharmacy · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeThe benefit of statins in acute stroke remains uncertain. Statins may prevent stroke recurrence during the acute stage of stroke via pleiotropic effects. However, statins may increase the risk of intracerebral hemorrhage. We investigated the effect and safety of rosuvastatin in acute stroke patients.
methodsThis randomized, double-blind, multi-center trial compared rosuvastatin 20 mg and placebo in statin-naïve stroke patients who underwent diffusion-weighted imaging (DWI) within 48 hours after symptom onset. The primary outcome was occurrence of new ischemic lesions on DWI at 5 or 14 days.
resultsThis trial was stopped early after randomization of 316 patients due to slow enrollment. Among 289 patients with at least one follow-up imaging, the frequency of new ischemic lesions on DWI was not different between groups (rosuvastatin: 27/137, 19.7% vs. placebo: 36/152, 23.6%) (relative risk 0.83, 95% confidence interval 0.53-1.30). Infarct volume growth at 5 days (log-transformed volume change, rosuvastatin: 0.2±1.0 mm(3) vs. placebo: 0.3±1.3 mm(3); P=0.784) was not different, either. However, hemorrhagic infarction or parenchymal/subarachnoid hemorrhage on gradient-recalled echo magnetic resonance imaging occurred less frequently in the rosuvastatin group (6/137, 4.4%) than the placebo group (22/152, 14.5%, P=0.007). Among 314 patients with at least one dose of study medication, progression or clinical recurrence of stroke tended to occur less frequently in the rosuvastatin group (1/155, 0.6% vs. 7/159, 4.4%, P=0.067). Adverse events did not differ between groups.
conclusionsThe efficacy of rosuvastatin in reducing recurrence in acute stroke was inconclusive. However, statin use was safe and reduced hemorrhagic transformation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.